Trial site
Gansu Wuwei Tumour Hospital
Wuwei, Gansu 730000, ChinaNot linked to an institution yet
- 8running trials
- 1closed trial
The trials here
What the 9 trials at this site are about, from their registry records.
- Phase
- Phase 37 trials
- Phase 11 trial
- Phase 21 trial
- Status
- Not yet recruiting5 trials
- Active, not recruiting3 trials
- Completed1 trial
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.4 trials
- Amgen1 trial
- Antengene Biologics Limited1 trial
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.1 trial
- RemeGen Co., Ltd.1 trial
- and 1 more
Running trials
Recruiting
A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07795346· Phase 3· Antengene Biologics Limited· Source
Contact: Peng Nie
Not yet recruiting
Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response
NCT07797231· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Wenhua Zhang, Bachelor
Recruiting
Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
NCT07385703· Phase 3· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source
Contact: Peng Nie, Master
Recruiting
Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
NCT06754891· Phase 1· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Contact: Linzhi Lu, Bachelor
Active, not recruiting
A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer
NCT06561607· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Recruiting
Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
NCT06155383· Phase 2· RemeGen Co., Ltd.· Source
Contact: Peng Niu, M.D
Active, not recruiting
To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer
NCT05365178· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Active, not recruiting
A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
NCT04344158· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error